We spoke with ANA Past President David Holtzman, MD, the Andrew B. and Gretchen P.
The ANA Q&A
ANA talked to Barbara S. Giesser, MD, FAAN, FANA, an internationally recognized clinician who has specialized in the care of persons with multiple sclerosis (MS) since 1982. Dr.
"We initially began examining the role of environmental pollution on ALS because of the high rates of ALS in the state of Michigan. Michigan’s economy has traditionally relied heavily on industries that produce large amounts of pollution such as automotive and defense manufacturing as well as agriculture.
"I think we can look broadly to research across the neurodegenerative diseases to assess how co-morbid pathologies might influence the rate of progression and the severity of expression of the disease. How does cerebrovascular disease affect PD disease course? How does sarcopenia and sedentary lifestyle affect disease progression, and can they be improved?
This month, the ANA talks with Jerome Graber, MD, MPH, an Associate Professor at the University of Washington who specializes in neuro-oncology. Dr. Graber discusses treatment options that improve quality of life for patients, his work with applications of neuroimaging, and more.
This month, the ANA speaks to Muhammad Alvi, MD, Assistant Professor, Medical Director of Stroke at J.W. Ruby Memorial Hospital, Berkeley Medical Center, WVU Rockefeller Neuroscience Institute. Dr. Alvi speaks about “silent strokes,” the use of Tenecteplase, and more.
This month, the ANA talks with this year’s recipient of the Distinguished Neurology Teacher Award, Ann Poncelet, MD, FAAN. Dr. Poncelet is the William G. Irwin Endowed Chair and Director of the Haile T. Debas Academy of Medical Educators at the University of California, San Francisco (UCSF), where she supports educators and the education mission at UCSF. Dr.
For this month’s ANA Member Highlight, we talk to Dr. Francesca Bagnato, MD, PhD, a dual-board neurology certified physician and faculty member at the Vanderbilt University Medical Center. Dr.
"It is exciting to witness numerous diverse and complementary efforts relying on genetic and pharmacological approaches to CMT. Some of these will surely bear fruit soon." ~ Dr. Florian P. Thomas
In conjunction with National Concussion Awareness Day and National Traumatic Brain Injury Awareness Month, the ANA talks with Ramon R. Diaz-Arrastia, MD, PhD, Director of the Traumatic Brain Injury Clinical Research Center at Penn Medicine in Philadelphia, Pennsylvania.